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NEOPLASIA
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma:
TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
Fanny Rubio-Moscardo, David Blesa, Cinta Mestre, Reiner Siebert, Theo Balasas, Adalberto Benito, Andreas Rosenwald, Joan Climent,
Jose I. Martinez, Markus Schilhabel, E. Lorraine Karran, Stefan Gesk, Manel Esteller, Ronald deLeeuw, Louis M. Staudt,
Jose Luis Fernandez-Luna, Daniel Pinkel, Martin J. S. Dyer, and Jose A. Martinez-Climent
Deletions of chromosome 8p are a recur-
rent event in B-cell non-Hodgkin lym-
phoma (B-NHL), suggesting the presence
of a tumor suppressor gene. We have
characterized these deletions using com-
parative genomic hybridization to microar-
rays, fluorescence in situ hybridization
(FISH) mapping, DNA sequencing, and
functional studies. A minimal deleted re-
gion (MDR) of 600 kb was defined in
chromosome 8p21.3, with one mantle cell
lymphoma cell line (Z138) exhibiting
monoallelic deletion of 650 kb. The MDR
extended from bacterial artificial chromo-
some (BAC) clones RP11-382J24 and
RP11-109B10 and included the tumor ne-
crosis factor–related apoptosis-inducing
ligand (TRAIL) receptor gene loci. Se-
quence analysis of the individual ex-
pressed genes within the MDR and DNA
sequencing of the entire MDR in Z138 did
not reveal any mutation. Gene expression
analysis and quantitative reverse tran-
scriptase–polymerase chain reaction
(QRT-PCR) showed down-regulation of
TRAIL-R1 and TRAIL-R2 receptor genes
as a consistent event in B-NHL with 8p21.3
loss. Epigenetic inactivation was ex-
cluded via promoter methylation analy-
sis. In vitro studies showed that TRAIL-
induced apoptosis was dependent on
TRAIL-R1 and/or -R2 dosage in most tu-
mors. Resistance to apoptosis of cell
lines with 8p21.3 deletion was reversed
by restoration of TRAIL-R1 or TRAIL-R2
expression by gene transfection. Our data
suggest that TRAIL-R1 and TRAIL-R2 act
as dosage-dependent tumor suppressor
genes whose monoallelic deletion can
impair TRAIL-induced apoptosis in B-cell
lymphoma. (Blood. 2005;106:3214-3222)
© 2005 by The American Society of Hematology
Introduction
B-cell non-Hodgkin lymphomas (B-NHLs) represent a heteroge-
neous group of disorders characterized in most cases by distinct
chromosomal translocations involving the immunoglobulin (IG)
genes.1 However, these translocations are not sufficient for tumor
formation, and other genetic abnormalities including concurrent
deregulation of other dominant oncogenes and/or inactivation of
tumor suppressor genes (TSGs) are necessary for lymphoma
development.2,3 Physical mapping of chromosome deletions in
tumor cells has facilitated the identification of classic TSGs such as
P16INK4a, ATM, P53, and RB, by demonstrating mutation of the
remaining alleles.4 These genes elicit a recessive phenotype and
encode proteins that affect several cellular pathways, such as those
controlling proliferation, apoptosis, differentiation, and genomic
integrity. However, in many other common regions of genomic
loss, no TSG carrying biallelic inactivation has been yet identified,
indicating that the “2-hit” requirement may not always be neces-
sary for tumorigenesis. Indeed, mutation of a single allele of P27
and P53 is sufficient to promote tumor formation in mice.5,6 These
haploinsufficient tumor suppressors retain a functional unmutated
allele and promote tumorigenesis through reduced gene dosage and
subsequently reduced protein levels.
In an initial study using conventional comparative genomic
hybridization (CGH) analysis, we reported the presence of a
putative tumor suppressor gene locus at the short arm of chromo-
some 8 (8p) in mantle cell lymphoma.7 Subsequent studies have
confirmed that this deletion is not only common in mantle cell
lymphoma but also in other B-cell malignancies.8-10 Chromosome
8p is also one of the most common sites of deletion in epithelial
tumors.11-17 This genomic loss has been repeatedly associated with
tumor progression and advanced or metastatic disease.7,9,11,17
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However, although various potential TSGs have been identified
across chromosome 8p, none fulfills the Knudson criteria (presence
of biallelic mutation) in a significant portion of tumors.12-16,18,19
These findings indicate that this chromosome arm may harbor one
or more haploinsufficient tumor suppressor genes.20,21
In contrast to carcinomas and sarcomas, a detailed search for a
common region of deletion across 8p has not been yet performed in
B-NHL. In this report, we delineated a common region of deletion
of approximately 600 kb in 8p21.3 in various B-NHL subtypes. In
vitro assays suggest that TRAIL-R1 and TRAIL-R2 may be the
target of the deletion and act as dosage-dependent tumor suppressor
genes by impairing the tumor necrosis factor–related apoptosis-
inducing ligand (TRAIL)–apoptotic pathway.
Material and methods
Tumor specimens
To screen for deletions of chromosome 8p, 45 B-cell lymphoma cell lines
were studied with genome-wide CGH to BAC microarrays (array CGH):
Granta 519, HBL2, SP49, Z138, REC1, NCEB1, JVM2, UPN1, and UPN2
(mantle cell lymphoma); OZ, VAL, Karpas 422, DOHH2, Karpas 353, PR1,
OCI-LY8, Karpas 231, SUDHL6, ROS50, RL, SCI1, BEVA, and Granta
452 (diffuse large B-cell lymphoma with t(14;18)(q32;q21)); CTB1,
MD901, MD903, RIVA, RCK8, and CIPULLO (diffuse large B-cell
lymphoma lacking t(14;18)); ELIJAH, NAB2, PL29018, SERAPHINA,
Wien133, P32, BALM9, BL41, CA46, Namalwa, and KHM10B (Burkitt
lymphoma); SSK41 and Karpas 1718 (marginal zone lymphoma); Karpas
1106 (primary mediastinal B-cell lymphoma); JVM13 (B-cell prolympho-
cytic leukemia); and GASH (hairy cell leukemia). References for their
derivation can be checked in a recently published manuscript.22 In addition,
lymph node and/or bone marrow samples from 22 patients with B-NHL (9
mantle cell lymphoma, 4 follicle center lymphoma, 4 diffuse large B-cell
lymphoma, 3 Burkitt lymphoma, 2 splenic marginal zone lymphoma), and 3
peripheral blood samples from patients with B-cell chronic lymphocytic
leukemia (B-CLL), all with suspected 8p deletion as documented by
previous cytogenetic or conventional CGH analyses, were also studied.
Additional lymph node specimens from 30 patients with B-NHL and 50
peripheral blood or bone marrow samples from patients with B-CLL were
studied with fluorescence in situ hybridization (FISH) using the BAC
RP11-89M8 that maps to the minimal deleted region (MDR). For muta-
tional analyses, an independent series of 117 lymph node samples from
untreated patients with different B-NHL subtypes was also studied. For this
study, approval was obtained from the University of Valencia and the
University of Navarra institutional review boards. Informed consent was
provided according to the Declaration of Helsinki.
Molecular cytogenetic analyses
Cell lines with chromosome 8p alterations were studied by G-banding and
color cytogenetics using reported methods.7 To validate the results of array
CGH, cell lines and selected patients with 8p deletion were analyzed with
FISH using 10 bacterial artificial chromosome (BAC) and P1-derived
artificial chromosome (PAC) clones mapped across 8p but not included in
the array: RP4-605G11 in 8p23.3, CTB-877B12 (8p23.2), GS1-877E9
(8p23.1), GS1-265M2 (8p23.1), GS1-148G17 (8p22), GS1-389E9 (8p21.2),
GS1-72M22 (8p21.1), GS1-398G7 (8p12), RP5-826O12 (8p11.22), and
GS1-392C11 (8p11.21). Clones were obtained from the Institute for
Molecular Biotechnology (Jena, Germany). To delineate the deleted
interval further, an additional 15 BAC clones mapped to 8p21 were also
studied by FISH in cell lines with the smallest interval of deletion
(RP11-110I16, RP11-67H12, RP11-420B22, RP11-233H21, RP11-677P13,
RP11-382J24, RP11-582J16, CTD-2238J6, RP11-459E5, RP11-89M8, CTD-
3188H20, RP11-177H13, RP11-204M16, RP11-288N10, RP11-158F9);
these were obtained from the CHORI (Oakland, CA) and from Research
Genetics (Invitrogen, Huntsville, AL). The centromere-specific chromo-
some 8 probe (CEP 8; Vysis, Downer’s Grove, IL) was cohybridized in
dual-color FISH experiments. BAC/PAC clones were cultured following
standard procedures; DNA was purified and labeled with SpectrumGreen-
dUTP or SpectrumOrange-dUTP (Vysis). FISH results were analyzed using
the QUIPS Imaging Software (Vysis) or the ISIS software (MetaSystems,
Altlusheim, Germany).
Parallel genomic and gene expression microarray analyses
An array-CGH microchip with 2460 BAC and P1 clones over the genome
(HumArray versions 1.4 and 2.0), which includes 69 clones mapped to
chromosome 8p, was applied as reported.23,24 After normalization of
individual array-CGH experiments, mean log2 ratios (tumoral DNA vs
control DNA) were plotted and the resultant graphs were converted to the
log2 domain. The observed log2 ratios were excluded from further analysis
if there were fewer than 2 replicate spots (out of 3) or if the standard
deviation of the replicates was above 0.2. The clones that were present in
fewer than 50% of the samples were also removed from the dataset.
Genomic losses were defined when log2 ratios were lower than 0.5 for
hemizygosity, and lower than 1.4 for homozygous deletion. To initially
investigate the expression of the genes mapped across 8p, the Lymphochip
cDNA microarrays were applied to 33 of the B-NHL cell lines, as
reported.25 Chromosome position of cDNA clones was determined accord-
ing to published genome sequences. Mean expression values for the
transcripts mapped across 8p were compared in deleted versus nondeleted
strains, using the Student t test. Values showing P below .05 were then
studied using the false discovery rate (FDR) test. An alpha value of less than
or equal to 0.01 was considered statistically significant. Supplementary
microarray data are provided in Table S1 on the Blood website; see the
Supplemental Tables link at the top of the online article.
Submegabase resolution tiling-set (SMRT) array CGH
To confirm and delineate the borders of the 8p21 deletions, and to screen for
undetected homozygous deletions within the region, 4 primary lymphoma
samples with 8p21 deletions and the Z138, JVM2, REC1, SP49, UPN1,
G519, HBL2, and NCEB1 cell lines were studied with submegabase
resolution tiling-set (SMRT) array CGH, as reported.26 This array includes
32 433 BACs covering completely the human genome, approximately 500
of which map to chromosome 8p.
Assessment of TRAIL receptor gene expression
Gene expression of the 4 TRAIL receptor genes, as well as of caspase-8,
was determined by reverse transcriptase–polymerase chain reaction (RT-
PCR). Total RNA was isolated from cell lines using the RNeasy Total RNA
Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol.
First-strand cDNA synthesis was performed on 1 g total RNA in a volume
of 20 L using Superscript II (Life Technologies, Bethesda, MD) and
oligo(dT). The specific primers used for mRNA amplification and PCR
conditions are shown in Table S2. In addition, quantitative reverse
transcriptase–PCR (QRT-PCR) assays for measurement of TRAIL-R1 and
TRAIL-R2 mRNA expression was also performed using the primers shown
in Table S2. QRT-PCR reactions were performed using the ABIPrism 7700
(PE Applied Biosystems, Foster City, CA) and the SYBr Green I dye.
mRNA expression of TRAIL-R1 and TRAIL-R2 was normalized to RNA
content for each sample by using glyceraldehyde-3-phosphate dehydroge-
nase (GADPH) and TBD gene products as internal controls. The relative
expression was calculated as the ratio of expression from each tumor
compared with the average expression from the blood mononuclear cells
obtained from 12 healthy donors. Cell surface expression of all the TRAIL
receptors was evaluated by flow cytometry, using the following monoclonal
antibodies: phycoerythrin (PE)–conjugated mouse antihuman TRAIL-R1
(IgG1; clone 69 036); TRAIL-R2 (IgG2b; clone 71 908); TRAIL-R3 (IgG1;
clone 90 906); TRAIL-R4 (IgG1; clone 104 918), according to the manufac-
turer’s instructions (R&D Systems, Minneapolis, MN). The PE-conjugated
mouse IgG1, k (clone MOPC-21) or IgG2b, k (clone 27-35) were used as
isotype controls (Becton Dickinson, San Jose, CA). A minimum of 10 000
cells was acquired for FACScalibur flow cytometer (BD Biosciences, San
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Jose, CA) and analyzed using Cell Quest software. All experiments were
performed at least in duplicate.
Mutation screening and promoter methylation study
Mutational analysis of genomic DNA from 26 cell lines (12 with 8p21 deletion
and 14 without) and 25 B-NHL primary samples (13 with 8p21 deletion and 12
without) was performed by single-strand conformational polymorphism
(SSCP) analysis and/or direct sequencing. According to the exon-intron
boundary sequences, we designed 35 sets of primers to amplify the entire
coding region, including each splicing site, of the TRAIL -R1, TRAIL-R2,
TRAIL-R3, and TRAIL-R4 genes, using the Primer 3 program (Table S1).
Mutation analysis of the TRAIL-R1 and TRAIL-R2 death domains was
performed in the remaining cell lines and in 117 additional patient samples. In
addition, PPP3CC and DBC2 genes were also sequenced; the complete PPP3CC
cDNA was amplified and direct-sequenced using 3 pairs of primers (Fw1:
5-TAAGGCTGCCCGAGGAGAAG-3, Rv1: 5-GGCATCATACACCTGT-
TCCGA-3, Fw2: 5-CATGAATGCAGGCATCTTACA-3, Rv2: 5-TCCATA-
AAGTTTGGAAGCCAG-3, Fw3: 5-CCAAGCCACAGGCTTTCCAT-3,
Rv3: 5-TGCACCCTCCAGGTTGAAGTT-3). For DCB2, the primers used
were: E1-4Fw: 5-CGTGCTCAGCAGGAAGAGATG-3, E1-4Rv: 5-CAGC-
CCACCAAGATGACAGG-3, E4-5Fw: 5-CCCAATTCCCTCCACCATGT-
3, E4-5Rv: 5-CAGAGTGGCCCTGGTGGTC-3, E5-6Fw: 5-TCCACCTC-
CTCCTCCAAGTTCT-3 E5-6Rv: 5-CCATCCAGTCACAGCTGGAAA-3,
E6-10Fw: 5-CCAACCGGGTTAAGGAGTGC-3 and E6-10Rv: 5-GGGT-
GATGCGGAAGAGCAG-3. Mutation status of exons 5 to 9 of P53 gene was
also analyzed in selected cell lines; PCR amplification products were purified
using a QIAquick PCR Purification Kit (Qiagen) and both DNA strands
sequenced by cycle sequencing. Sequence variations were compared with
published sequences.Amethylation-specific PCR (MSP) method for the analysis
of TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4 was applied to the cell lines
and primary tumors. Genomic DNA was isolated from cell lines and patient
samples using standard procedures. Approximately 1 g DNA was bisulfite-
modifed using previously reported methods.27 Sequence primers for the MSP
analysis of TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4 were designed in
the 5 untranslated region CpG island of the published sequences near translation
start site (Table S2). PCR reactions were hot-started at 95°C for 10 minutes, by
using 0.25 L (5 U/L) of Fast Start DNA polymerase (Roche, Barcelona,
Spain). Reactions were performed at 58°C to 60°C annealing temperature. Each
PCR reaction was loaded on a 2.5% agarose gel stained with ethidium bromide
and directly visualized under UV illumination. Cp Genome Universal Methyl-
ated DNA (Serogicals, Norcross, GA) modified with bisulfite was used as a
methylated DNA positive control.
DNA sequencing of 650 kb spanning the MDR
in the Z138 cell line
The Z138 cell line was shown to have the shortest interval of loss in 8p21.3.
To screen for mutations in the nondeleted allele, a series of primers was
designed to amplify the DNA sequence of the 1 Mb segment between
BACs RP11-177H13 (LOXL2 gene) and CTD-2036J7 (PPP3C gene). For
resequencing, genomic DNA was amplified by a nested PCR approach.
Primers were designed by PRIMER3 (http://fokker.wi.mit.edu/primer3/)
using sequences masked by REPEATMASKER. For the first PCR, 100 ng
genomic DNA, 10 pmol of each primer, and Taq polymerase (Qiagen,
Germany) were used. PCR products were sequenced using primers for the
second PCR and Big Dye Terminator Cycle Sequencing kit v3.0 (PE
Applied Biosystems). Sequencing reactions were electrophoresed on
ABI3700 automated sequencers. Base calling was performed using PHRED,
the program for automated sequencer traces.28,29 Trace files were as-
sembled, inspected visually, and edited in the GAP4 program.30 Sequences
were compared with the current UCSC database. Complete sequencing data
are provided in Table S3 (http://genome.imb-jena.de/mantle_lymphom/).
TRAIL sensitivity assays
Cell lines were cultured according to standard conditions. As a positive
control, the Jurkat cell line (DSMZ, Braunschweig, Germany), which is
sensitive to TRAIL-induced apoptosis, was also included in the study.
Exponentially growing cells were plated at 1  106 cells/mL of RPMI
medium in 24-well microtiter plates. Recombinant human TRAIL (Biomol
Research Lab, Plymouth Meeting, MA) at concentrations of 0, 100, 300,
and 500 ng/mL was added. After 24 and 48 hours, apoptotic cells were
quantified by staining with fluorescein isothiocyanate (FITC)–conjugated
Annexin V and propidium iodide according to the manufacturer’s instruc-
tions (BD Pharmingen). Cell fluorescence was detected on a FACScalibur
(Becton Dickinson). A minimum of 10 000 cells were acquired and
analyzed using Cell Quest analysis software. All experiments were
performed at least in triplicate.
Transfection assays
Full-length human TRAIL-R1 and TRAIL-R2 cDNA clones (accession nos.
BC012 866 and BC001 281, respectively) were obtained from Invitrogen
(ID clone 3 857 315 human TRAIL-R1 and ID clone 3 458 466 human
TRAIL-R2). Both cDNAs were amplified by PCR with primers listed in
Table S2. PCR products were digested with XbaI and EcoRI (TRAIL-R1) or
SpeI and EcoRI (TRAIL-R2) and subcloned into the expression vector
pcDNA3-Flag31 and sequenced. Namalwa and SUDHL6 cell lines, both
carrying the 8p21 deletion, were transfected with 10 g pcDNA3 Flag-
TRAIL-R1 or pcDNA3 Flag-TRAIL-R2 by electroporation using an
Electro Cell Manipulator ECM600 (BTX, Holliston, MA). Transfected
cells were selected in the presence of 1 mg/mL G418 (Invitrogen)
containing media, and subsequently maintained with 0.25 mg/mL to 0.5
mg/mL G418. Protein expression of TRAIL-R1 and TRAIL-R2 was
analyzed by Western blot and flow cytometry. Apoptosis was determined
before and after 24 hours of treatment with TRAIL by staining with
FITC-conjugated annexin V and propidium iodide.
Results
Delineation of an MDR in 8p21.3 in B-NHL
To determine the frequency of 8p genomic loss we initially
performed BAC array CGH analysis of the B-NHL cell lines and
patient samples. Search for genomic losses identified the deletion
of chromosome 8p in 12 of 45 (27%) B-NHL cell lines of different
origins (Table 1), and in 20 primary lymphoma samples, correspond-
ing to 18 B-NHL (9 mantle cell lymphoma, 3 follicle center
lymphoma, 2 diffuse large B-cell lymphoma, 2 Burkitt lymphoma,
2 splenic marginal zone lymphoma) and 2 B-CLL. Comparison of
the data from these tumors allowed the delineation of an MDR in
8p21.3 comprising approximately 1.5 Mb of genomic sequence
(Figure 1A). These data were primarily based on the array CGH
analysis of 2 cell lines (the MCL-derived Z138 and PR1, derived
from a patient with follicle center lymphoma) and patient no. P005
with mantle cell lymphoma, all of which showed interstitial
deletions in 8p21 below the resolution of conventional CGH
(Figure 1B). Karyotype analysis showed different alterations
leading to the loss of chromosome 8p, such as unbalanced
translocation, interstitial deletion, or isochromosome formation
(Table 1 and Figure 1C). Results of array CGH were independently
confirmed by applying FISH with probes mapping to 8p that were
not included in the array, but also using clones from the array
(Figure 1D). At this level of resolution all deletions were
heterozygous.
To delineate the deletion further, BAC/PAC clones covering
the 1.5 Mb deleted area were first mapped to cell lines with the
smallest deletions using FISH, narrowing the commonly deleted
interval down to approximately 0.6 Mb. The MDR extended
from BACs RP11-382J24 and RP11-109B10 at telomeric and
centromeric boundaries, respectively. Notably, one mantle cell
lymphoma cell line (Z138) exhibited a monoallelic deletion of
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650 kb, which included the TRAIL-R1 gene just at the centro-
meric border. Second, a SMRT array CGH system spanning the
entire 8p arm with approximately 500 BACs was applied to
selected cell lines and primary tumors. The SMRT array CGH
confirmed 8p21.3 deletions in the 8 tumors with known deletion,
including the consensus MDR in all cases, but again, did not
detect any homozygous losses. In the Z138 cell line, only 7 of
the approximately 500 BACs covering 8p were deleted, confirm-
ing the region of loss of approximately 600 kb between the
TRAIL-R1 and PPP3CC genes (Figure 1E). To evaluate further
the extent to which the deletion affects B-cell malignancies, we
FISHed 80 clinical samples using BAC RP11-89M8. Seven
patients showed deletion: 4 with diverse B-NHL subtypes (4 of
30, 13%) and 3 with B-CLL (3 of 50, 6%).
Mutation analysis of the 8p21.3 MDR in B-NHL
In the MDR there are 10 known genes, including 3 of the 4 tumor
necrosis factor (TNF) receptor superfamily members: the transmem-
brane proapoptotic death receptor TRAIL-R2 (TNFRSF10A, DR5),
and 2 decoy receptors TRAIL-R3 (TNFRSF10C, DcR1) and
TRAIL-R4 (TNFRS10D, DcR2).15,32,33 Other genes within the MDR
were SCAM1, PDLIM2, DBC1, BIN3, EGR3, PEBP4, and
RHOBTB2/DBC2. Notably, the TRAIL-R1 gene (TNFRSF10A,
DR4) was just at the centromeric border of the deletion in the Z138
cell line, but it was shown to be deleted in all the remaining 31
lymphomas with 8p21.3 deletion. At the telomeric border of the
deletion, the PPP3C gene was not included in the MDR based on
the data from the PR1 cell line (Figure 1E). Next we sought
potentially pathogenic mutations in the genes within the MDR.
Given the functions of the TRAIL receptor genes in signaling
apoptosis, we focused on these genes initially. The complete coding
regions plus splicing intron-exon sites of the 4 TRAIL-receptor
genes were sequenced in 26 cell lines and 25 primary samples. In
addition, because mutations in the death domain of TRAIL-R1 and
TRAIL-R2 have been reported at low frequency in human tu-
mors,34,35 both death domains were sequenced in an additional 117
B-NHL biopsies. No mutation was detected in tumors with and
without 8p deletions, although known and several novel polymor-
phisms were observed (Table S4). Mutations were also excluded in
2 putative TSGs mapped to 8p21, deleted in breast cancer 2
(DBC2) and PPP3CC. In these, several polymorphisms were
identified, which are shown in Supplemental Table D. In addition,
the interval of genomic loss in 8p21.3 in the Z138 cell line,
consisting of 650 kb of genomic DNA, which was the shortest
deletion ranging from BAC RP11-177H13 to BAC CTD-2036J07,
was completely sequenced. No unexpected changes other than
common polymorphisms in the genes within the MDR were found
(Table S3).
Hemizygous loss of TRAIL receptor genes results in
down-regulation of cell surface expression
of TRAIL receptor proteins
To determine whether chromosome 8p deletion affected gene
expression across the genomic region at 8p, we assessed gene
Figure 1. Delineation of a common interval of deletion
of 0.6 Mb in 8p21.3 in B-cell lymphomas. (A) Array
CGH analysis shows deleted clones (red), genomic gains
(green), nondeleted probes (white), and noninformative
clones (orange). Asterisks indicate the clones used for
verifying array CGH results by FISH analysis in selected
cell lines. (B) Array CGH analysis of chromosome 8 in
PR1 and Z138 cell lines, and in patient P005, showing
genomic deletions in 8p21 undetected using conventional
CGH. (C) G-banding cytogenetic, FISH, and SKY (spec-
tral karyotyping) analyses show deletion of chromosome
8p and translocation of the remaining nondeleted allele in
OCI-Ly8 cell line in a complex translocation. (D) FISH
analysis of 8p21.3 deletion using BAC RP11-89M8 (green)
and a centromeric chromosome 8 probe (red). The
examples correspond to 2 patients with transformed
splenic marginal zone lymphoma (left) and DLBCL (right).
(E) Map of chromosome 8p21.3 including the clones used
for narrowing down the commonly deleted interval by
array CGH, SMRT array, and FISH (black) (UCSC, May
2004 freeze).53 Inset shows the SMRT array CGH analy-
sis of 2 selected cell lines and one primary tumor.
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expression using the Lymphochip cDNA microarray. Among 79
genes/ESTs that mapped to 8p in the Lymphochip microarray,
only 5 (6%) showed statistically significant down-regulation in
cell lines with 8p loss with respect to those with both alleles
intact (Figure 2A). Notably, only 2 of these down-regulated
cDNAs mapped into the critical region at 8p21.3, and both
corresponded to TRAIL-R2. The other cDNAs corresponded to
HSPC035 at 8p12, PPP3CC at 8p21, and FBXO25 at 8p23.3.
TRAIL-R1 is not included in the Lymphochip microarray.
RT-PCR analysis showed that TRAIL-R1 and TRAIL-R2 were
expressed in all cell lines, whereas expression of TRAIL-R3 was
absent in 12 of 12 (100%) samples with 8p deletion and in 7 of 8
(87%) of nondeleted specimens. TRAIL-R4 was also expressed
in all tumors (20 of 20, 100%), and expression of caspase-8 was
present in all cell lines (Figure 2B). QRT-PCR indicated
decreased expression levels of TRAIL-R1 and TRAIL-R2 in cell
lines carrying deletion of 8p21.3 (P  .01). Measurement of cell
surface expression of TRAIL receptors using flow cytometry
showed that both TRAIL-R1 and TRAIL-R2 were underex-
pressed in deleted cell lines, whereas TRAIL-R3 and TRAIL-R4
were similarly expressed both in deleted and nondeleted cell
lines (Figure 2C). Because promoter methylation may be
responsible for down-regulation of the TRAIL receptor genes in
cancer,36 we studied the methylation pattern of these genes in
cell lines and primary tumors. Methylation of TRAIL-R1 and
TRAIL-R2 was not observed in 26 tumors carrying deletion of
8p, but was observed in 5 and 7 of 38 nondeleted cell lines and
biopsy samples (13% and 18%, respectively). Methylation of
TRAIL-R3 was identified in 12 of 20 tumors (60%) with 8p
deletions, but also in 22 of 38 nondeleted samples (55%),
indicating a good correlation with expression data in most
tumors. On the contrary, TRAIL-R4 was rarely methylated, and
only in nondeleted tumor cells (Figure 2D).
Sensitivity to TRAIL-induced apoptosis is dependent on
TRAIL-R1 and TRAIL-R2 gene and protein dosage
Regulation and maintenance of expression of death and decoy
receptors is critical for controlling apoptosis.33,37,38 Examination of
TRAIL-induced apoptotic response in the lymphoma cell lines
after exposure to different TRAIL doses revealed that TRAIL-
mediated apoptosis was directly related to TRAIL-R1 and TRAIL-R2
expression in most tumors, but not to that of TRAIL-R3/TRAIL-R4
(Figure 3A). Resistance to apoptosis was higher in cell lines with
8p deletion versus nondeleted strains: 7 (78%) of 9 versus 2 (25%)
of 8 of tumors showed less than 25% cell apoptosis after a 24-hour
incubation with 500 ng TRAIL, respectively. The Z138 cell line,
which exhibits deletion of TRAIL-R2 and showed TRAIL-R1 to be
mapped at the centromeric border of the deletion in 8p21.3, was
sensitive to TRAIL-induced apoptosis; expression levels of the
receptors were higher for TRAIL-R1 than for TRAIL-R2, suggest-
ing that in Z138 cells the TRAIL-induced sensitivity may be
mediated via TRAIL-R1 signaling. In the MD901 cell line, which
shows deletion of both TRAIL-R1 and TRAIL-R2 genes and is
sensitive to TRAIL-induced apoptosis, expression of TRAIL-R1
was very low but TRAIL-R2 was expressed at higher levels,
perhaps indicating signaling through TRAIL-R2 receptor. Because
polymorphisms in the untranslated regions of TRAIL receptor
genes have been involved in the translational control of TRAIL-R2
expression in melanoma cells,39 we checked whether a 3UTR
region of TRAIL-R2 as well as other known and novel polymor-
phisms observed in the TRAIL receptors correlated with the levels
Figure 2. Gene expression analysis of tumors with 8p deletion. (A) Representation of gene expression analysis of cell lines with deletion of 8p (left) and those without
genomic deletion (right). Array indicates the position of TRAIL receptor genes in the array. The 5 clones with statistically significant decreased expression in cell lines with
deletion versus nondeleted strains are shown. (B) RT-PCR analysis for TRAIL receptor genes and the caspase 8 gene. (C) Flow cytometry analysis for TRAIL receptor genes
showed reduced expression for TRAIL-R1 and TRAIL-R2 in deleted versus nondeleted cell lines and patient samples. (D) Methylation analysis: representative examples of cell
line samples. U indicates unmethylated; M, methylated; IVD, methylated positive control. In red, cell lines showing methylation of the corresponding gene.
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of expression of the receptors and/or the resistance to TRAIL-
induced apoptosis. None of the polymorphisms was associated
with differences in expression or sensitivity to TRAIL-induced
apoptosis (Table 1). To investigate whether the P53 gene, which
directly binds to the TRAIL-R2 promoter and signals apoptotic
death,40 carried mutations that may have influenced in the TRAIL
sensitivity, we screened for P53 mutations. Inactivating mutations
were observed in one of the sensitive cell lines (MD901) but also in
resistant strains (Namalwa), excluding correlation with TRAIL-R1/
TRAIL-R2 expression or with TRAIL-mediated apoptosis.
Restoration of TRAIL-R1 and TRAIL-R2 expression reversed
resistance to TRAIL-mediated apoptosis
In search for a model, we evaluated whether variation in TRAIL-R1
and/or TRAIL-R2 expression levels after gene transfection en-
hanced TRAIL-induced apoptosis in B-cells. FLAG-tagged
TRAIL-R1 and TRAIL-R2 expression constructs were transfected
alone and cotransfected simultaneously into 5 lymphoma cell lines
with 8p loss (Namalwa, SUDHL6, REC1, JVM2, and NCEB1). We
only obtained stable transfections of TRAIL-R2 in Namalwa cells,
derived from Burkitt lymphoma, and of TRAIL-R1 in the SUDHL6
cell line, derived from diffuse large B-cell lymphoma with
t(14;18)(q32;q21). Both cell lines showed deletion of 8p21.3,
including TRAIL-R1 and TRAIL-R2 gene loci, and were resistant to
TRAIL-induced apoptosis. In both, expression of TRAIL-R1 and
R2 was increased by less than 2-fold, resembling the expression
levels of most cell lines with 2 8p21.3 alleles. Increased TRAIL-R2
expression in Namalwa cells and TRAIL-R1 expression in SUDHL6
were both associated with restoration of TRAIL-induced sensitiv-
ity, whereas nontransfected cell lines used as controls remained
resistant (Figure 3B). These data indicated that the extrinsic
apoptotic pathway was not structurally damaged in these 2 cell
lines and that TRAIL-induced apoptosis was reversible with
expression of the receptors, depending on TRAIL-R1 and TRAIL-R2
protein dosage. Therefore, TRAIL-R1 and TRAIL-R2 seem to show
a gene-dosage effect that can be disrupted by chromosome
deletion, thus impairing TRAIL-induced apoptosis in B cells.
Discussion
Genetic analysis has suggested that deletion of sequences that map
to chromosome 8p may be critical for tumorigenesis in epithelial
carcinomas as well as in hematologic malignancies.21 However, a
marked heterogeneity in the different publications has led to the
description of several critical regions of deletion in 8p. Here, we
delineate an MDR in chromosome 8p21.3 that is coincident with
some of the reported deletions in other tumors. Among the previous
reports, Hamaguchi et al15 used representational difference analysis
to narrow down a region of homozygous deletion in breast cancer
overlapping with ours that contained TRAIL-R2 but not TRAIL-R1,
whereas Swalwell et al41 analyzed microsatellite markers for loss of
heterozygosity (LOH) in prostate tumors and delineated an MDR
of 1.5 Mb in 8p21.3 including the 4 TRAIL receptor genes. In 2
additional publications using microsatellite analysis, common
regions of deletions spanning 8p21.3 were identified in non–small
lung and colorectal carcinomas.42,43 With the combination of
high-resolution array CGH and FISH mapping, we defined the
MDR to 600 kb in 8p21.3 that may harbor one or more tumor
suppressor genes involved not only in B-cell lymphoma, but also in
other cancer types.
Monoallelic deletion with concurrent mutation of the remaining
allele and/or promoter methylation is a common mechanism of
inactivation for tumor suppressor genes. Among the genes located
within the MDR, the TRAIL receptor genes were selected initially
based on their roles in signaling apoptosis and because mutations of
TRAIL-R1 and TRAIL-R2 had been reported in lymphoma and in
other cancers.34,35 However, we failed to identify any pathogenic
mutation or promoter methylation in TRAIL-R1 and TRAIL-R2. In
addition, obvious pathogenic mutations were excluded in the
candidate tumor suppressor DBC2, contained within the MDR, and
in the PPP3C gene, located at the telomeric border of the MRD.
Sequencing of the entire interval of MDR in the Z138 cell line
failed to identify sequence changes in all the genes within the MDR
as well. Notably, the gene encoding the decoy receptor TRAIL-R3
showed frequent hemizygous loss plus silencing of the second
allele by promoter methylation, therefore fulfilling the criteria for
“2-hit” TSGs. However, this decoy receptor does not contain a
functional domain, and seems to block TRAIL-induced apoptosis
by competing with TRAIL-R1 and TRAIL-R2.33,37 Therefore, this
Figure 3. In vitro and in vivo assays implicating TRAIL-R2 as a candidate
dosage-dependent tumor suppressor in B-cell lymphoma. (A) TRAIL-induced
apoptosis response in SU-DHL6 (resistant to TRAIL-induced apoptosis) and VAL
(sensitive to TRAIL-induced apoptosis) cell lines. Cell surface expression of the 4
TRAIL receptors was determined by flow cytometry. Fresh SUDHL6 and VAL cells
were incubated in the presence of recombinant human TRAIL (500 ng/mL). After 24
hours, cell death was quantified by flow cytometric analysis after staining with
FITC-conjugated Annexin V and propidium iodide; the percentage of dead cells is
indicated. (B) Namalwa and SUDHL6 cell lines, both carrying 8p21 deletion, were
transfected with pcDNA3 Flag-TRAIL-R1 or pcDNA3 Flag-TRAIL-R2. Transfected
cells were selected in the presence of G418-containing media, and subsequently
maintained with 0.25 mg/mL to 0.5 mg/mL G418. Protein expression TRAIL-R1 and
TRAIL-R2 were analyzed by Western blot and flow cytometry. Flow cytometry
analysis of cell surface expression of TRAIL-R1 and TRAIL-R2 receptors after cell
transfection in SU-DHL6 and Namalwa is shown. Apoptosis was determined before
and after 24 hours of treatment with TRAIL. Restoration of expression levels of
TRAIL-R1 and TRAIL-R2 by less than 2-fold was associated with increased
TRAIL-induced apoptosis, as shown by the percentage of apoptotic cells in the cell
lines transfected with the empty vector compared with those transfected with
pcDNA-TRAIL-R1 and R2.
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gene may not be considered a tumor suppressor gene a priori, but
we cannot exclude that TRAIL-R3 could have unreported functions
besides its role as decoy receptor and might be implicated in the
lymphoma pathogenesis. It should be noted that within the MDR
described here there are no identified micro-RNA genes.
In the absence of any pathogenic mutations there is currently no
conclusive proof of which, if any, of the genes studied represent
true oncogenic targets. To explain the apparent lack of a conven-
tional tumor suppressor gene in 8p, gene inactivation through
alternative mechanisms such as haploinsufficiency were postu-
lated. Our data suggest that deletion-induced haploinsufficiency of
TRAIL-R1/R2 can impair TRAIL-induced apoptosis and thus
contribute to tumorigenesis in B cells through a gene dosage effect.
Indeed, in our system model, overexpression of TRAIL-R1 and -R2
was massive but only by less than 2-fold, mimicking the difference
between haploinsufficiency and wild-type tumors without 8p21.3
deletions. In agreement with our results, Chaib et al20 reported that
haploinsufficiency and transcriptional down-regulation for genes
mapping to 8p, including TRAIL-R1/R2, are coincident in human
prostate tumors. Also in agreement with these data, several reports
indicate that TRAIL can induce rejection or apoptosis of tumor
cells.44-48 Cretney et al48 reported that TRAIL knock-out mice were
more susceptible to experimental and spontaneous tumor metasta-
sis, whereas Takeda et al46 found that development of spontaneous
tumors in p53/ mice was promoted by neutralization of TRAIL.
However, the role of the TRAIL receptors’ deficiency in suppress-
ing tumorigenesis in vivo has been investigated only recently.
Diehl et al49 reported the generation of TRAIL receptor (TRAIL-R)–
deficient mice (mDR5, mTRAILR2, or mKILLER), the only
full-length TRAIL receptor in mouse with equal homology to
human TRAIL-R1 and TRAIL-R2. Mice were born at the expected
Mendelian ratios and showed no developmental abnormalities. The
authors defined a role for TRAIL-R signaling independent of its
ability to initiate apoptosis in sensitive cells. Remarkably, these
animals did not develop tumors spontaneously. More importantly,
crossing of the TRAIL-R–deficient mice with p53/ mice and
with ApcMIN/ mice, 2 well-established models of tumorigenesis,
did not affect the onset or growth of T-cell thymomas and intestinal
tumors, respectively.50 The role of TRAIL-R deficiency was not
evaluated, however, in a B-cell lymphoma mouse model, and thus
cannot be fully compared with our results. Finnberg et al51 created
another knock-out mouse lacking TRAIL-R. This mouse was
viable and developed normally with the exception of enlarged
thymus. Authors showed that loss of TRAIL-R diminished apopto-
sis in immortalized cells. In addition, they showed that TRAIL-R
plays a role in the DNA damage response of the immune cells of the
thymus and of the spleen and in particular in the lymphocytes of the
white pulp. These data may help to interpret our results, as we can
hypothesize that TRAIL-R1 and -R2 show different function in
B-cell lymphocytes, including modulation of TRAIL-induced
apoptosis. Consequently, TRAIL-R1 and/or TRAIL-R2 might show
tumor suppressor activity in B-cell lymphoma, as we have initially
shown in this manuscript. We may also speculate on different roles
of TRAIL receptors in humans compared with mice, which only
bear one TRAIL receptor instead of the 2 observed in humans and
primates.52 Further experimental studies will clarify whether
TRAIL-R deficiency may enhance tumor formation in well-
characterized B-cell lymphoma mouse models.
In summary, we have delineated a novel MDR in chromosome
8p21.3 and have provided data that suggest that TRAIL-R1 and
TRAIL-R2 genes are the targets of the deletion. These genes may
act as dosage-dependent suppressor genes by impairing the TRAIL-
apoptotic pathway in B-cell lymphoma.
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